论文部分内容阅读
目的探讨高通量血液透析治疗尿毒症患者的临床疗效。方法 76例尿毒症患者,利用计算机随机分组法分为对照组及观察组,各38例。对照组患者行低通量血液透析治疗,观察组患者行高通量血液透析治疗。测定两组治疗前、治疗1年后血肌酐(Scr)、尿素氮(BUN)、β_2-微球蛋白(β2-MG)及甲状旁腺激素(PTH)水平变化。结果治疗前,两组患者的Scr、BUN、β_2-MG、PTH水平比较,差异均无统计学意义(P>0.05);治疗后,两组患者的Scr、BUN、β_2-MG、PTH水平均较本组治疗前降低,且观察组治疗后Scr(97.68±10.02)μmol/L、BUN(6.81±2.03)mmol/L、β_2-MG(179.01±24.97)pg/ml、PTH(3.02±0.45)mg/L水平低于对照组[(112.65±10.78)μmol/L、(10.23±3.12)mmol/L、(190.59±25.38)pg/ml、(4.21±0.45)mg/L],差异均具有统计学意义(P<0.05)。结论对尿毒症患者采取高通量血液透析治疗的效果显著,有效清除β_2-MG、PTH等较大分子的毒素物质,值得推广。
Objective To investigate the clinical effect of high-flux hemodialysis on patients with uremia. Methods Totally 76 uremic patients were divided into control group and observation group randomly by computer. Control group patients underwent low-flux hemodialysis treatment, observation group patients underwent high-flux hemodialysis treatment. The levels of serum creatinine (Scr), blood urea nitrogen (BUN), β2-microglobulin (β2-MG) and parathyroid hormone (PTH) were measured before treatment and after 1 year of treatment in both groups. Results Before treatment, the levels of Scr, BUN, β_2-MG and PTH in both groups had no significant difference (P> 0.05). After treatment, the levels of Scr, BUN, β_2-MG and PTH (P <0.01), PTH (3.02 ± 0.45) pg / ml, BUN (6.81 ± 2.03) mmol / L, mg / L was lower than that in the control group [(112.65 ± 10.78) μmol / L, (10.23 ± 3.12) mmol / L, (190.59 ± 25.38) pg / ml, (4.21 ± 0.45) mg / L] Significance (P <0.05). Conclusions High-throughput hemodialysis is effective in treating patients with uremia. Effective removal of toxoid substances such as β_2-MG and PTH is worth promoting.